SynthesisAntimicrobial resistance and infection control2023
A meta-analysis on the prevalence of resistance of Staphylococcus aureus to different antibiotics in Nigeria.
Synthesis in Antimicrobial resistance and infection control, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Nasopharyngeal Carriage Rate, Risk Factors, and Co-Resistance Patterns of Methicillin-Resistant Staphylococcus aureus in Ethiopia: Systematic Review and Meta-Analysis.MicrobiologyOpen · 2026Pooled it
- Prevalence of Streptococcus pneumoniae and Staphylococcus aureus co-colonization in healthy children under five years: a systematic review.BMC pediatrics · 2026Pooled it
- Global prevalence of macrolide-resistantFrontiers in microbiology · 2025Pooled it
- A systematic review and meta-analysis on the prevalence of extended-spectrum beta-Lactamase-ProducingAfrican health sciences · 2024Pooled it
- Article
- A retrospective assessment of antimicrobial resistance patterns in WHO-access, watch, and reserve-classified antibiotics across two large hospitals in a resource-limited setting.Scientific reports · 2026Article
- Antimicrobial resistance in uropathogens in Nigeria: pathogen profiles, resistance burden, surveillance and stewardship considerations.Frontiers in microbiology · 2026Article
- Gene copy-number features generalize better than SNPs for antimicrobial resistance prediction in Staphylococcus aureus.npj antimicrobials and resistance · 2025Article
- Metallic nanoparticles in the treatment of staphylococcus infections: a scoping review.BMC pharmacology & toxicology · 2025Article
- Bacterial profile, their antimicrobial susceptibility pattern and associated factors of otitis media among children at selected private hospitals in Hargeisa City, Somaliland.BMC infectious diseases · 2025Article
- Profile and evolution of antimicrobial resistance genes in Staphylococcus aureus whole genomes in Africa revealed by phylogeography and bioinformatics.Scientific reports · 2025Article
- Conventional Antimicrobial and Medicinal Plants from a Traditional Medicine Market in South Africa: An Interactive Antimicrobial and Toxicity Study.Antibiotics (Basel, Switzerland) · 2025Article
- Prevalence, Antimicrobial Resistance, and Virulence Potential ofAntibiotics (Basel, Switzerland) · 2025Article
- Nasal carriage rate and multiple antimicrobial resistance indices ofAfrican journal of laboratory medicine · 2025Article
- Antimicrobial resistance inOne health (Amsterdam, Netherlands) · 2024Article
- Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy AgainstAntibiotics (Basel, Switzerland) · 2024Review
- Nanocomposites: silver nanoparticles and bacteriocins obtained from lactic acid bacteria against multidrug-resistant Escherichia coli and Staphylococcus aureus.World journal of microbiology & biotechnology · 2024Review
- Update on Urinary Tract Infection Antibiotic Resistance-A Retrospective Study in Females in Conjunction with Clinical Data.Life (Basel, Switzerland) · 2024Article
- Forecasting the development of antimicrobial resistance ofFrontiers in oral health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRapid emergence of multidrug resistant Staphylococcus aureus has resulted to difficulty in treatment of infections caused by such strains. The aim of this meta-analysis study was to determine the pooled prevalence of resistance of S. aureus to different antibiotics in Nigeria.
methodsLiterature search for studies was done using Google scholar, PubMed, Science direct, and African Journal Online. The prevalence of S. aureus resistance to different antibiotics was evaluated using the meta-analysis proportion command in MedCalc software version 20.0 adopting a rand effect model. I
resultsA total of 40, 682 studies were retrieved through the database search of which 98 studies met the study inclusion criteria. Prevalence of resistance of S. aureus to different antibiotics ranges from 13 to 82%. Results showed a very high degree of resistance to penicillin G (82% [95% confidence interval (CI) 61%, 0.96%]), cloxacillin (77% [95% CI 64%, 88%]), amoxacillin (74% [95% CI 66%, 81%]), cefuroxime (69% [95% CI 51%, 85%]), ampicillin (68% [95% CI 53%, 81%]). Moderately resistance to erythromycin (47% [95% CI 40%, 53%]), chloramphenicol (47% [95% CI 37%, 56%]), methicillin (46% [95% CI 37%, 56%]), ofloxacin (24% [95% CI 18%, 31%]) and rifampicin 24% [95% CI 6%, 48%]). Low resistance was observed in vancomycin 13% (95% CI 7%, 21%). For each individual meta-analysis, high heterogeneity was observed with I
conclusionThis meta-analysis study established that S. aureus in Nigeria has developed resistance to commonly used antibiotics such as the beta-lactam class antibiotics, sulphonamides, tetracyclines, chloramphenicol, and vancomycin. Hence it is imperative to develop programs to promote rational use of antimicrobial agents, infection prevention and control to reduce the incidence of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.